



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
INDIVIDUAL:			
WITNESS NAME: APRIL HATCH		PHONE NUMBER:	
BUSINESS/ORGANIZATION NAME:		TITLE:	
ADDRESS:			
CITY:		STATE:	ZIP:
EMAIL:	ATTENDANCE:		SUBMIT DATE: 2/28/2023 12:00 AM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
INDIVIDUAL:			
WITNESS NAME: ARNIE C "HONEST-ABE" DIENOFF-STATE PUBLIC ADVOCATE		PHONE NUMBER:	
BUSINESS/ORGANIZATION NAME:		TITLE:	
ADDRESS:			
CITY:		STATE:	ZIP:
EMAIL: arniedienoff@yahoo.com	ATTENDANCE: Written		SUBMIT DATE: 2/28/2023 11:27 PM

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

I am in Support of this Bill with the use and possibilities of Natural Remedies. This is the first-step over medicines and chemicals. I believe in Natural Medicine.



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
INDIVIDUAL:			
WITNESS NAME: CARL SHEPARD		PHONE NUMBER:	
BUSINESS/ORGANIZATION NAME:		TITLE:	
ADDRESS:			
CITY:		STATE:	ZIP:
EMAIL:	ATTENDANCE:		SUBMIT DATE: 2/28/2023 12:00 AM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023
COMMITTEE: Veterans		
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES		
WITNESS NAME		
REGISTERED LOBBYIST:		
WITNESS NAME: CHRISTOPHER HAMMANN		PHONE NUMBER: 573-619-0184
REPRESENTING: GREAT STATE STRATEGIES		TITLE:
ADDRESS:		
CITY: KANSAS CITY		STATE: MO
		ZIP:
EMAIL:	ATTENDANCE:	SUBMIT DATE: 2/28/2023 12:00 AM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.		



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
INDIVIDUAL:			
WITNESS NAME: DANIEL HARKINS		PHONE NUMBER:	
BUSINESS/ORGANIZATION NAME:		TITLE:	
ADDRESS:			
CITY:		STATE:	ZIP:
EMAIL:	ATTENDANCE:		SUBMIT DATE: 2/28/2023 12:00 AM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
REGISTERED LOBBYIST:			
WITNESS NAME: SUSAN GRIFFITH		PHONE NUMBER: 573-424-4951	
REPRESENTING: CERTIFIED ALTERNATIVE MEDICINE PROVIDERS		TITLE:	
ADDRESS: 244 FAIRWAY GREEN DRIVE			
CITY: O'FALLON		STATE: MO	ZIP: 63368
EMAIL:	ATTENDANCE:	SUBMIT DATE: 2/28/2023 12:00 AM	
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023
COMMITTEE: Veterans		
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES		
WITNESS NAME		
INDIVIDUAL:		
WITNESS NAME: TYLER MARLER DO		PHONE NUMBER:
BUSINESS/ORGANIZATION NAME:		TITLE:
ADDRESS:		
CITY:		STATE: ZIP:
EMAIL: tmarler@atsu.edu	ATTENDANCE: Written	SUBMIT DATE: 2/27/2023 10:03 PM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.		

I agree with a physicians right to recommend alternative and natural medicines and treatments that have evidence of efficacy but may not be recognized universallly as the preferred or standard treatment method. I do stand by the oath that a physician takes to do no harm and the side effects of such alternative or natural medicine should be elucidated to the patient.



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input checked="" type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
BUSINESS/ORGANIZATION:			
WITNESS NAME: WILLIAM WISNER		PHONE NUMBER: 314-358-5088	
BUSINESS/ORGANIZATION NAME: GRUNT STYLE FOUNDATION		TITLE: EXECUTIVE DIRECTOR	
ADDRESS: 7003 SPAVALE DRIVE			
CITY: HIGH RIDGE		STATE: MO	ZIP: 63049
EMAIL:	ATTENDANCE:	SUBMIT DATE: 2/28/2023 12:00 AM	
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023
COMMITTEE: Veterans		
TESTIFYING: <input type="checkbox"/> IN SUPPORT OF <input checked="" type="checkbox"/> IN OPPOSITION TO <input type="checkbox"/> FOR INFORMATIONAL PURPOSES		
WITNESS NAME		
REGISTERED LOBBYIST:		
WITNESS NAME: JEFF HOWELL		PHONE NUMBER: 573-636-5151
REPRESENTING: MISSOURI STATE MEDICAL ASSOCIATION		TITLE: EVP
ADDRESS: 113 MADISON STREET, P.O. BOX 1028		
CITY: JEFFERSON CITY		STATE: MO
		ZIP: 65102
EMAIL: jhowell@msma.org	ATTENDANCE: In-Person	SUBMIT DATE: 2/28/2023 8:16 AM

**THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.
MSMA opposes the dispensation of any Schedule 1 drug.**



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023	
COMMITTEE: Veterans			
TESTIFYING: <input type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input checked="" type="checkbox"/> FOR INFORMATIONAL PURPOSES			
WITNESS NAME			
INDIVIDUAL:			
WITNESS NAME: JOSHUA S. SIEGEL		PHONE NUMBER:	
BUSINESS/ORGANIZATION NAME:		TITLE:	
ADDRESS:			
CITY:		STATE:	ZIP:
EMAIL:	ATTENDANCE:		SUBMIT DATE: 2/28/2023 12:00 AM
THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.			



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023
COMMITTEE: Veterans		
TESTIFYING: <input type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input checked="" type="checkbox"/> FOR INFORMATIONAL PURPOSES		
WITNESS NAME		
BUSINESS/ORGANIZATION:		
WITNESS NAME: RAMON MARTINEZ		PHONE NUMBER: 573-316-5262
BUSINESS/ORGANIZATION NAME: MOST POLICY INITIATIVE		TITLE: PHD
ADDRESS: 238 E HIGH ST.		
CITY: JEFFERSON CITY		STATE: MO ZIP: 65101
EMAIL: ramon@mostpolicyinitiative.org	ATTENDANCE: In-Person	SUBMIT DATE: 2/28/2023 8:06 AM

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

MOST Policy Initiative is a non partisan non profit research program. We have written a short Research Brief on natural medicines for trauma/palliative/hospice care patients and on medical psilocybin which we are happy to make available to the members of the committee. Our over 200 notes are on our website mostpolicyinitiative.org Research Summary - Q: What is the therapeutic potential of psychotropic compounds like psilocybin ? First, important to understand the implications of Schedule I drug listing. The Controlled Substances Act has a list of drugs that either the FDA, DEA, or Congress can assign compounds to that heavily restrict not only access but federal funding to these drugs. Licensed researchers are often under heavy scrutiny (DEA) but also often have to raise private funds. As such long term and large scale efficacy of these drugs is unknown compared to robust data for other therapeutics. However, private funding (\$420 M in 2019) has been invested in this research. FDA has streamlined their regulatory process, putting psilocybin on the "Breakthrough Therapy" list, meaning if the drug provides a substantial improvement over current options, could get approved. What is the data on Psilocybin?: Is a hallucinatory compound that has low potential for abuse, no potential for addiction or overdose. Side effects can include nausea, vomiting, muscle weakness, headache, higher blood pressure, fear or paranoia, and reduction in coordination The drugs shows the strongest evidence for use on treatment-resistant depression and anxiety, especially for terminally ill patients. The drug shows promise for use in PTSD, but studies on trauma affected patients are still lacking. Data on other compounds mentioned in these bills, like MDMA is still developing, but is showing efficacy in PTSD patients in a large trial. Spravato is a synthesized form of ketamine FDA-approved for the treatment adult major depressive disorder, but with high cost barriers. Two states (OR and WA) have legalized the use of medicinal psilocybin under supervision in treatment centers. Federal Right to Try Act allows people access to these compounds if they have gone through at least 1 small, early trial; Religious Freedom Restoration Act allows access to certain hallucinogens like peyote and ayahuasca for ceremonial purposes. Various jurisdictions have already approved cannabis for medicinal use, personal use, or decriminalization despite Schedule I listing by federal government.



MISSOURI HOUSE OF REPRESENTATIVES
WITNESS APPEARANCE FORM

BILL NUMBER: HB 869		DATE: 2/28/2023
COMMITTEE: Veterans		
TESTIFYING: <input type="checkbox"/> IN SUPPORT OF <input type="checkbox"/> IN OPPOSITION TO <input checked="" type="checkbox"/> FOR INFORMATIONAL PURPOSES		
WITNESS NAME		
BUSINESS/ORGANIZATION:		
WITNESS NAME: RAMON MARTINEZ		PHONE NUMBER: 573-316-5262
BUSINESS/ORGANIZATION NAME: MOST POLICY INITIATIVE		TITLE: PHD
ADDRESS: 238 E HIGH ST.		
CITY: JEFFERSON CITY		STATE: MO ZIP: 65101
EMAIL: ramon@mostpolicyinitiative.org	ATTENDANCE: In-Person	SUBMIT DATE: 2/28/2023 8:14 AM

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

MOST Policy Initiative is a non profit non partisan research program. We have written a short Research Brief on natural medicines for trauma/palliative/hospice care patients and on medical psilocybin which we are happy to make available to the members of the committee. Our over 200 notes are on our website mostpolicyinitiative.org Research Summary - Q: What is the therapeutic potential of psychotropic compounds like psilocybin ? First, important to understand the implications of Schedule I drug listing. The Controlled Substances Act has a list of drugs that either the FDA, DEA, or Congress can assign compounds to that heavily restrict not only access but federal funding to these drugs. Licensed researchers are often under heavy scrutiny (DEA) but also often have to raise private funds. As such long term and large scale efficacy of these drugs is unknown compared to robust data for other therapeutics. However, private funding (\$420 M in 2019) has been invested in this research. FDA has streamlined their regulatory process, putting psilocybin on the "Breakthrough Therapy" list, meaning if the drug provides a substantial improvement over current options, could get approved. What is the data on Psilocybin?: Is a hallucinatory compound that has low potential for abuse, no potential for addiction or overdose. Side effects can include nausea, vomiting, muscle weakness, headache, higher blood pressure, fear or paranoia, and reduction in coordination The drugs shows the strongest evidence for use on treatment-resistant depression and anxiety, especially for terminally ill patients. The drug shows promise for use in PTSD, but studies on trauma affected patients are still lacking. Data on other compounds mentioned in these bills, like MDMA is still developing, but is showing efficacy in PTSD patients in a large trial. Spravato is a synthesized form of ketamine FDA-approved for the treatment adult major depressive disorder, but with high cost barriers. Two states (OR and CO) have legalized the use of medicinal psilocybin under supervision in treatment centers. Federal Right to Try Act allows people access to these compounds if they have gone through at least 1 small, early trial; Religious Freedom Restoration Act allows access to certain hallucinogens like peyote and ayahuasca for ceremonial purposes. Various jurisdictions have already approved cannabis for medicinal use, personal use, or decriminalization despite Schedule I listing by federal government.